Cargando…

Temozolomide-Induced RNA Interactome Uncovers Novel LncRNA Regulatory Loops in Glioblastoma

SIMPLE SUMMARY: Glioblastoma (GBM) is the most aggressive brain tumor and most resistant to therapy. The identification of novel predictive biomarkers or targets to counteract chemoresistance, requires a better understanding of the GBM primary response to therapy. The aim of our study was to assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Fritah, Sabrina, Muller, Arnaud, Jiang, Wei, Mitra, Ramkrishna, Sarmini, Mohamad, Dieterle, Monika, Golebiewska, Anna, Ye, Tao, Van Dyck, Eric, Herold-Mende, Christel, Zhao, Zhongming, Azuaje, Francisco, Niclou, Simone P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563839/
https://www.ncbi.nlm.nih.gov/pubmed/32927769
http://dx.doi.org/10.3390/cancers12092583
_version_ 1783595577906298880
author Fritah, Sabrina
Muller, Arnaud
Jiang, Wei
Mitra, Ramkrishna
Sarmini, Mohamad
Dieterle, Monika
Golebiewska, Anna
Ye, Tao
Van Dyck, Eric
Herold-Mende, Christel
Zhao, Zhongming
Azuaje, Francisco
Niclou, Simone P.
author_facet Fritah, Sabrina
Muller, Arnaud
Jiang, Wei
Mitra, Ramkrishna
Sarmini, Mohamad
Dieterle, Monika
Golebiewska, Anna
Ye, Tao
Van Dyck, Eric
Herold-Mende, Christel
Zhao, Zhongming
Azuaje, Francisco
Niclou, Simone P.
author_sort Fritah, Sabrina
collection PubMed
description SIMPLE SUMMARY: Glioblastoma (GBM) is the most aggressive brain tumor and most resistant to therapy. The identification of novel predictive biomarkers or targets to counteract chemoresistance, requires a better understanding of the GBM primary response to therapy. The aim of our study was to assess the molecular response of GBM to the standard of care chemotherapy by temozolomide (TMZ). We established a comprehensive map of gene expression changes after treatment and discovered that GBM cells elicit a coordinated gene expression program after chemotherapy that differs between sensitive and resistant cells. We found that a novel class of genes expressed as long non-coding RNAs (lncRNAs) is involved in gene regulatory circuits in GBM and could represent novel markers of GBM patient prognosis. By shedding light on the involvement of the non-coding genome in GBM, our results may provide new mechanistic insight on lncRNAs and their importance in chemoresistance. ABSTRACT: Resistance to chemotherapy by temozolomide (TMZ) is a major cause of glioblastoma (GBM) recurrence. So far, attempts to characterize factors that contribute to TMZ sensitivity have largely focused on protein-coding genes, and failed to provide effective therapeutic targets. Long noncoding RNAs (lncRNAs) are essential regulators of epigenetic-driven cell diversification, yet, their contribution to the transcriptional response to drugs is less understood. Here, we performed RNA-seq and small RNA-seq to provide a comprehensive map of transcriptome regulation upon TMZ in patient-derived GBM stem-like cells displaying different drug sensitivity. In a search for regulatory mechanisms, we integrated thousands of molecular associations stored in public databases to generate a background “RNA interactome”. Our systems-level analysis uncovered a coordinated program of TMZ response reflected by regulatory circuits that involve transcription factors, mRNAs, miRNAs, and lncRNAs. We discovered 22 lncRNAs involved in regulatory loops and/or with functional relevance in drug response and prognostic value in gliomas. Thus, the investigation of TMZ-induced gene networks highlights novel RNA-based predictors of chemosensitivity in GBM. The computational modeling used to identify regulatory circuits underlying drug response and prioritizing gene candidates for functional validation is applicable to other datasets.
format Online
Article
Text
id pubmed-7563839
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75638392020-10-27 Temozolomide-Induced RNA Interactome Uncovers Novel LncRNA Regulatory Loops in Glioblastoma Fritah, Sabrina Muller, Arnaud Jiang, Wei Mitra, Ramkrishna Sarmini, Mohamad Dieterle, Monika Golebiewska, Anna Ye, Tao Van Dyck, Eric Herold-Mende, Christel Zhao, Zhongming Azuaje, Francisco Niclou, Simone P. Cancers (Basel) Article SIMPLE SUMMARY: Glioblastoma (GBM) is the most aggressive brain tumor and most resistant to therapy. The identification of novel predictive biomarkers or targets to counteract chemoresistance, requires a better understanding of the GBM primary response to therapy. The aim of our study was to assess the molecular response of GBM to the standard of care chemotherapy by temozolomide (TMZ). We established a comprehensive map of gene expression changes after treatment and discovered that GBM cells elicit a coordinated gene expression program after chemotherapy that differs between sensitive and resistant cells. We found that a novel class of genes expressed as long non-coding RNAs (lncRNAs) is involved in gene regulatory circuits in GBM and could represent novel markers of GBM patient prognosis. By shedding light on the involvement of the non-coding genome in GBM, our results may provide new mechanistic insight on lncRNAs and their importance in chemoresistance. ABSTRACT: Resistance to chemotherapy by temozolomide (TMZ) is a major cause of glioblastoma (GBM) recurrence. So far, attempts to characterize factors that contribute to TMZ sensitivity have largely focused on protein-coding genes, and failed to provide effective therapeutic targets. Long noncoding RNAs (lncRNAs) are essential regulators of epigenetic-driven cell diversification, yet, their contribution to the transcriptional response to drugs is less understood. Here, we performed RNA-seq and small RNA-seq to provide a comprehensive map of transcriptome regulation upon TMZ in patient-derived GBM stem-like cells displaying different drug sensitivity. In a search for regulatory mechanisms, we integrated thousands of molecular associations stored in public databases to generate a background “RNA interactome”. Our systems-level analysis uncovered a coordinated program of TMZ response reflected by regulatory circuits that involve transcription factors, mRNAs, miRNAs, and lncRNAs. We discovered 22 lncRNAs involved in regulatory loops and/or with functional relevance in drug response and prognostic value in gliomas. Thus, the investigation of TMZ-induced gene networks highlights novel RNA-based predictors of chemosensitivity in GBM. The computational modeling used to identify regulatory circuits underlying drug response and prioritizing gene candidates for functional validation is applicable to other datasets. MDPI 2020-09-10 /pmc/articles/PMC7563839/ /pubmed/32927769 http://dx.doi.org/10.3390/cancers12092583 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fritah, Sabrina
Muller, Arnaud
Jiang, Wei
Mitra, Ramkrishna
Sarmini, Mohamad
Dieterle, Monika
Golebiewska, Anna
Ye, Tao
Van Dyck, Eric
Herold-Mende, Christel
Zhao, Zhongming
Azuaje, Francisco
Niclou, Simone P.
Temozolomide-Induced RNA Interactome Uncovers Novel LncRNA Regulatory Loops in Glioblastoma
title Temozolomide-Induced RNA Interactome Uncovers Novel LncRNA Regulatory Loops in Glioblastoma
title_full Temozolomide-Induced RNA Interactome Uncovers Novel LncRNA Regulatory Loops in Glioblastoma
title_fullStr Temozolomide-Induced RNA Interactome Uncovers Novel LncRNA Regulatory Loops in Glioblastoma
title_full_unstemmed Temozolomide-Induced RNA Interactome Uncovers Novel LncRNA Regulatory Loops in Glioblastoma
title_short Temozolomide-Induced RNA Interactome Uncovers Novel LncRNA Regulatory Loops in Glioblastoma
title_sort temozolomide-induced rna interactome uncovers novel lncrna regulatory loops in glioblastoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563839/
https://www.ncbi.nlm.nih.gov/pubmed/32927769
http://dx.doi.org/10.3390/cancers12092583
work_keys_str_mv AT fritahsabrina temozolomideinducedrnainteractomeuncoversnovellncrnaregulatoryloopsinglioblastoma
AT mullerarnaud temozolomideinducedrnainteractomeuncoversnovellncrnaregulatoryloopsinglioblastoma
AT jiangwei temozolomideinducedrnainteractomeuncoversnovellncrnaregulatoryloopsinglioblastoma
AT mitraramkrishna temozolomideinducedrnainteractomeuncoversnovellncrnaregulatoryloopsinglioblastoma
AT sarminimohamad temozolomideinducedrnainteractomeuncoversnovellncrnaregulatoryloopsinglioblastoma
AT dieterlemonika temozolomideinducedrnainteractomeuncoversnovellncrnaregulatoryloopsinglioblastoma
AT golebiewskaanna temozolomideinducedrnainteractomeuncoversnovellncrnaregulatoryloopsinglioblastoma
AT yetao temozolomideinducedrnainteractomeuncoversnovellncrnaregulatoryloopsinglioblastoma
AT vandyckeric temozolomideinducedrnainteractomeuncoversnovellncrnaregulatoryloopsinglioblastoma
AT heroldmendechristel temozolomideinducedrnainteractomeuncoversnovellncrnaregulatoryloopsinglioblastoma
AT zhaozhongming temozolomideinducedrnainteractomeuncoversnovellncrnaregulatoryloopsinglioblastoma
AT azuajefrancisco temozolomideinducedrnainteractomeuncoversnovellncrnaregulatoryloopsinglioblastoma
AT niclousimonep temozolomideinducedrnainteractomeuncoversnovellncrnaregulatoryloopsinglioblastoma